Q-omics provides the consensus-scored UBBP4 profile across patient tissues and cancer cell-line models. UBBP4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, UBBP4 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, UBBP4 RNA expression shows 17,151 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, KICH, and ACC as cancer lineages where UBBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBBP4 survival associations across molecular data types. UBBP4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBBP4 RNA expression–survival associations across cancer types. High UBBP4 expression shows unfavorable associations in STAD, KICH, LGG and LUSC, but favorable associations in KIRC and UCS. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for UBBP4 RNA expression.
This table summarizes UBBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBBP4 shows lower tumor expression in KICH, LUAD, LUSC and THCA and higher tumor expression in COAD and BRCA. The KICH box plot shows higher UBBP4 RNA expression in normal versus tumor tissue (log2 FC = −1.143, t-test p < 0.001).
This table shows molecular features associated with UBBP4 in patient tissues and cancer cell lines. In patient samples, UBBP4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBBP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
